number back to the baseline. Consistent with an effect of IL-8 blockade on the increase of CD15+CD14- myeloid cells, single
nuclear RNA sequencing analysis of the tumor tissues showed that the innate immune response and cytokine
response pathways in the myeloid cell cluster were activated by IL-8 blockade.

Conclusions This result suggested that IL-8 blockade did not simply inhibit myeloid cells as previously anticipated, but
potentiated myeloid cells for the innate immune response and concomitant production of type I cytokines. Such immune
responses may subsequently activate the effector T cells as the single nuclear RNA sequencing analysis demonstrated
enhanced activation signals in the T cell cluster from the tumors treated by anti-IL-8 antibodies. Taken together, this
study supports further testing of anti-IL-8 antibodies including B108-IL8 and HuMax-IL8 in combination with anti-PD-1 anti-
odies for PDAC treatment.

Disclosure Information P. Li: None. N. Rozich: None. J. Wang: None. J. Gai: None. J. Wang: None. Y. Xu: None.
K. Li: None. Y. Fune: None. A. Osipov: None. C. Wolfgang: None. M. Lei: A. Employment (full or part-time); Significant;
NovaRock. T. Liang: None. L. Zheng: B. Research Grant (principal investigator, collaborator or consultant and pending
grants as well as grants already received); Significant; Bristol-Meyer Squibb, Merck, iTeos, Amgen, NovaRock, Inxmed,
Halozyme. E. Ownership Interest (stock, stock options, patent or other intellectual property); Significant; Alphamab,
Mingruzhiyao. F. Consultant/Advisory Board; Significant; Bio-sion, Alphamab, NovaRock, Akrevia/Xilio, Ambx, Novagne-
sis, Datarevive, Snow Lake Capitals, Mingruzhiyao. Other; Significant; Aduro Biotech.